Summary
In a total of 62 samples of cerebrospinal fluid (CSF) and an equal number of serum samples obtained from 16 patients suffering from amyotrophic lateral sclerosis, 22 patients suffering from miscellaneous neurological diseases, and 24 controls, lead was measured by atomic absorption spectrophotometry. No statistical difference in lead concentration was found between the above three groups.
Similar content being viewed by others
References
Conradi, S., Ronnevi, L.-O., and Stibler, H., J. neurol. Sci.37 (1978) 95.
Ronnevi, L.-O., Conradi, S., and Nise, G., J. neurol. Sci.57 (1982) 143.
Waldron, H., and Stöfen, D., Academic Press, London-New York 1975.
Cambell, S., Richman, D., Crayton, J., and Arnason, B., J. Neurol. Neurosurg. Psychiat.33 (1970) 877.
Stober, T., Stelte, W., and Kunze, K., J. neurol. Sci.61 (1983) 21.
Manton, W., and Cook, J., Neurology29 (1979) 612.
House, A., Abbot, R., Davidson, D., Ferguson, J., and Lenman, J., Br. med. J.2 (1978) 1684.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kapaki, E., Segditsa, J., Zournas, C. et al. Determination of cerebrospinal fluid and serum lead levels in patients with amyotrophic lateral sclerosis and other neurological diseases. Experientia 45, 1108–1110 (1989). https://doi.org/10.1007/BF01950171
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01950171